Sumit Chanda, Ph.D.

Sumit Chanda's Research Focus

Infectious Diseases, HIV/AIDS, Pandemic Influenza, Inflammatory/Autoimmune Disease, Arthritis, Crohn’s Disease (Colitis), Psoriasis, Scleroderma, Systemic Lupus Erythematosus, Cancer
Viruses are obligate pathogens, and therefore their survival is dependent upon their ability to exploit host cellular machinery. Concurrently, viruses must also successfully evade immune surveillance mechanisms, including first-line (innate) defense systems. The Chanda lab is interested in unraveling the molecular bases for these complex host-pathogen interactions, which will not only provide insight into viral pathogenesis, but key regulators of inflammation and innate immunity in cancer.

Sumit Chanda's Research Report

We are studying cellular proteins required for both influenza A and retrovirus/HIV infection. Also, we are investigating novel molecules that regulate or respond to Pattern Recognition Receptor (PRR) signaling. Taken together, we aim to elucidate the repertoire of host proteins required for viral infection, and understand the molecular strategies adapted by these viruses as countermeasures to innate immune responses. 

To understand these events on a global level, our lab uses a series of systems-level approaches, including genome-wide RNAi, proteomics and protein-protein interaction (PPI) analysis, and high content imaging. These, and other, tools are helping us to build a comprehensive cellular "roadmap" exploited by these viruses to enable their propagation within a cell. These studies are expected to provide unprecedented insight into the molecular circuitry commandeered by these pathogens to establish infection, and will offer new opportunities for the development of "next generation" host factor and immune-mediated antivirals.

Sumit Chanda's Bio

Sumit Chanda earned his Ph.D. from Stanford University in 2001, and received his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF). He subsequently transitioned to a Group Leader position, and established his research group in the Division of Cellular Genomics at GNF. In 2007, he joined the Infectious and Inflammatory Disease Center at Sanford-Burnham Medical Research Institute as an Associate Professor. Dr. Chanda also holds an Adjunct Professor appointment at the Salk Institute for Biological Studies, as well as a Visiting Scientist position at the Genomics Institute of the Novartis Research Foundation.
 

Other Appointments

Adjunct Professor, Salk Institute for Biological Sciences
Visiting Scientist, The Genomics Institute of the Novartis Research Foundation
Visiting Scientist, The Scripps Research Institute


IPP Accessory

Publications

NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses.

Guo H, König R, Deng M, Riess M, Mo J, Zhang L, Petrucelli A, Yoh SM, Barefoot B, Samo M, Sempowski GD, Zhang A, Colberg-Poley AM, Feng H, Lemon SM, Liu Y, Zhang Y, Wen H, Zhang Z, Damania B, Tsao LC, Wang Q, Su L, Duncan JA, Chanda SK, Ting JP

Cell Host Microbe 2016 Apr 13 ;19(4):515-528

A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals.

Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Burgstaller-Muehlbacher S, Pache L, De Jesus PP, Hull MV, Chang M, Chan JF, Cao J, Poon VK, Herbert K, Nguyen TT, Pu Y, Nguyen C, Rubanov A, Martinez-Sobrido L, Liu WC, Miorin L, White KM, Johnson JR, Benner C, Sun R, Schultz PG, Su A, Garcia-Sastre A, Chatterjee AK, Yuen KY, Chanda SK

bioRxiv 2020 Apr 17 ;

Sensor Sensibility-HIV-1 and the Innate Immune Response.

Yin X, Langer S, Zhang Z, Herbert KM, Yoh S, König R, Chanda SK

Cells 2020 Jan 20 ;9(1)

Show All Select Publications

Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs In Vivo.

Pache L, Marsden MD, Teriete P, Portillo AJ, Heimann D, Kim JT, Soliman MSA, Dimapasoc M, Carmona C, Celeridad M, Spivak AM, Planelles V, Cosford NDP, Zack JA, Chanda SK

Cell Rep Med 2020 Jun 23 ;1(3):100037

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling.

Miorin L, Kehrer T, Sanchez-Aparicio MT, Zhang K, Cohen P, Patel RS, Cupic A, Makio T, Mei M, Moreno E, Danziger O, White KM, Rathnasinghe R, Uccellini M, Gao S, Aydillo T, Mena I, Yin X, Martin-Sancho L, Krogan NJ, Chanda SK, Schotsaert M, Wozniak RW, Ren Y, Rosenberg BR, Fontoura BMA, García-Sastre A

Proc Natl Acad Sci U S A 2020 Nov 10 ;117(45):28344-28354

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.

Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, Narayanan A, Majowicz SA, Kwong EM, McVicar RN, Thacker BE, Glass CA, Yang Z, Torres JL, Golden GJ, Bartels PL, Porell RN, Garretson AF, Laubach L, Feldman J, Yin X, Pu Y, Hauser BM, Caradonna TM, Kellman BP, Martino C, Gordts PLSM, Chanda SK, Schmidt AG, Godula K, Leibel SL, Jose J, Corbett KD, Ward AB, Carlin AF, Esko JD

Cell 2020 Nov 12 ;183(4):1043-1057.e15

The E3 Ubiquitin-Protein Ligase Cullin 3 Regulates HIV-1 Transcription.

Langer S, Yin X, Diaz A, Portillo AJ, Gordon DE, Rogers UH, Marlett JM, Krogan NJ, Young JAT, Pache L, Chanda SK

Cells 2020 Sep 1 ;9(9)

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.

Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, Burgstaller-Muehlbacher S, De Jesus PD, Teriete P, Hull MV, Chang MW, Chan JF, Cao J, Poon VK, Herbert KM, Cheng K, Nguyen TH, Rubanov A, Pu Y, Nguyen C, Choi A, Rathnasinghe R, Schotsaert M, Miorin L, Dejosez M, Zwaka TP, Sit KY, Martinez-Sobrido L, Liu WC, White KM, Chapman ME, Lendy EK, Glynne RJ, Albrecht R, Ruppin E, Mesecar AD, Johnson JR, Benner C, Sun R, Schultz PG, Su AI, García-Sastre A, Chatterjee AK, Yuen KY, Chanda SK

Nature 2020 Oct ;586(7827):113-119

Sensor Sensibility-HIV-1 and the Innate Immune Response.

Yin X, Langer S, Zhang Z, Herbert KM, Yoh S, König R, Chanda SK

Cells 2020 Jan 20 ;9(1)

Show All Publications